New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer Recurrence
1 other identifier
observational
1,000
1 country
1
Brief Summary
In this study, mass spectrometry was used to analyze immune inflammation-related protein complexes, post-translational modified glycopeptide omics and tumor-related metabolomics in serum, respectively, in order to find potential metabolic small molecule biomarkers or marker profiles that can be used for early diagnosis of cancer recurrence.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2022
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 3, 2022
CompletedFirst Submitted
Initial submission to the registry
June 4, 2022
CompletedFirst Posted
Study publicly available on registry
June 8, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 3, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
March 3, 2026
CompletedJune 8, 2022
March 1, 2022
2 years
June 4, 2022
June 4, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Immune Inflammation-Related Protein Complexes
The change of immune inflammation-related protein complexes
2 years
Interventions
No intervention in clinical treatment
Eligibility Criteria
Before treatment, after surgery, during chemotherapy, and after chemotherapy, patients with confirmed ovarian epithelial cancer had different time cutoff points until clinically confirmed patients recurred.
You may qualify if:
- Female
- A diagnosed patient with epithelial ovarian cancer
- Age ≤ 70
You may not qualify if:
- Male
- Suffering from other malignant tumors
- Non-compliant patient
- Age above 70
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Biospecimen
1 mL of serum
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 4, 2022
First Posted
June 8, 2022
Study Start
March 3, 2022
Primary Completion
March 3, 2024
Study Completion
March 3, 2026
Last Updated
June 8, 2022
Record last verified: 2022-03
Data Sharing
- IPD Sharing
- Will not share